LianBio (NASDAQ:LIAN) Shares Up 2% – Still a Buy?

Shares of LianBio (NASDAQ:LIAN) rose 2% during trading on Wednesday . The stock traded as high as $0.39 and last traded at $0.38. Approximately 51,338 shares traded hands during trading, a decline of 95% from the average daily volume of 1,037,083 shares. The stock had previously closed at $0.37.

LianBio Price Performance

The business’s fifty day simple moving average is $0.21 and its two-hundred day simple moving average is $0.23. The company has a market cap of $41.06 million, a PE ratio of -0.47 and a beta of 0.23.

LianBio Company Profile

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.